BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15

BTIG analyst Ryan Zimmerman has maintained a Buy rating on AVITA Medical (NASDAQ: RCEL) and raised the price target from $11 to $15. This adjustment reflects a positive outlook for the company's performance.